View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Market Data
April 8, 2022

Global clinical trials activity decreased 8.3% in Q1 2022 over 4Q average

By Carmen

The global clinical trials activity saw a decrease of 8.3% in Q1 2022, when compared with the rolling average of the last four quarters (Q1 2021 to Q4 2021), according to GlobalData.

Of the overall activity, industry sponsored trials accounted for a 48.1% share in Q1 2022, marking a decrease of 0.8% in the total share when compared with the four-quarter average.

Non-industry sponsored trials accounted for a 51.9% share of all the clinical trials globally in Q1 2022, marking an increase of 0.8% in the overall share when compared with the four-quarter average.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Top therapy areas for industry and non-industry sponsored clinical trials in Q1 2022

Oncology was the leading therapy area for industry sponsored clinical trials in Q1 2022, accounting for a 30.7% share of all trials.

This was followed by the following therapy areas: Infectious Disease with a 15.2% share, Central Nervous System with a 14.3% share, Metabolic Disorders with a 7.4% share and Cardiovascular with a 6.1% share.

In the last four quarters, Oncology held a lead over other therapy areas for industry sponsored clinical trials with a 27.6% share, followed by Infectious Disease with a 17.1% share, Central Nervous System with a 14.2% share, Metabolic Disorders with a 7.8% share, and Cardiovascular with a 7.7% share.

Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022
Therapy Area 4-Quarter Avg. Q1 2022 Activity
Oncology 27.6% 30.7% Increase
Infectious Disease 17.1% 15.2% Decrease
Central Nervous System 14.2% 14.3% Increase
Metabolic Disorders 7.8% 7.4% Decrease
Cardiovascular 7.7% 6.1% Decrease
Immunology 5.5% 5.7% Increase
Gastrointestinal 6.7% 5.3% Decrease
Respiratory 5.7% 4.7% Decrease
Dermatology 4.6% 4.4% Decrease
Musculoskeletal Disorders 4.1% 4.1% Decrease
Hematological Disorders 2.7% 3.3% Increase
Ophthalmology 2.9% 3.0% Increase
Genito Urinary System And Sex Hormones 2.6% 2.7% Increase
Genetic Disorders 1.7% 1.8% Increase
Women’s Health 1.9% 1.4% Decrease
Ear Nose Throat Disorders 1.5% 1.3% Decrease
Hormonal Disorders 0.7% 0.6% Decrease
Male Health 1.0% 0.4% Decrease
Mouth and Dental Disorders 0.6% 0.4% Decrease
Nutritional Disorders 0.3% 0.3% Decrease
Non Malignant Disorders 0.2% 0.2% Decrease

Central Nervous System was the leading therapy area for non-industry sponsored clinical trials in Q1 2022, accounting for a 25.5% share of all trials.

This was followed by the following therapy areas: Oncology with a 22.0% share, Infectious Disease with a 12.5% share, Cardiovascular with a 9.8% share, and Gastrointestinal with a 6.2% share.

In the last four quarters, Central Nervous System System held a lead over others for non-industry sponsored clinical trials with an average share of 24.1%, followed by Oncology with a 23.3% share, Infectious Disease with a 15.0% share, Cardiovascular with an 8.9% share, and Gastrointestinal with a 6.5% share.

Non-Industry sponsored trials activity: 4-Quarter Avg. vs Q1 2022
Therapy Area 4-Quarter Avg. Q1 2022 Activity
Central Nervous System 24.1% 25.5% Increase
Oncology 23.3% 22.0% Decrease
Infectious Disease 15.0% 12.5% Decrease
Cardiovascular 8.9% 9.8% Increase
Gastrointestinal 6.5% 6.2% Decrease
Metabolic Disorders 5.3% 6.1% Increase
Musculoskeletal Disorders 5.0% 5.3% Increase
Women’s Health 4.5% 4.2% Decrease
Respiratory 4.3% 3.8% Decrease
Immunology 3.3% 3.4% Increase
Hematological Disorders 2.9% 3.3% Increase
Genito Urinary System And Sex Hormones 2.8% 2.9% Increase
Dermatology 2.9% 2.4% Decrease
Mouth and Dental Disorders 2.5% 2.4% Decrease
Ophthalmology 1.9% 1.9% Decrease
Ear Nose Throat Disorders 1.1% 1.1% Decrease
Hormonal Disorders 0.8% 1.1% Increase
Genetic Disorders 0.6% 0.6% Decrease
Male Health 0.7% 0.6% Decrease
Nutritional Disorders 0.7% 0.5% Decrease
Non Malignant Disorders 0.3% 0.3% Decrease

Top regions in industry and non-industry sponsored clinical trials activity in Q1 2022

Asia-Pacific held the top position for industry sponsored clinical trials activity in Q1 2022 with a 48.0% share, compared to 54.6% in the last four quarters.

North America stood at second place with a 36.0% share in Q1 2022, over 31.3% in the last four quarters, followed by Europe with a 28.3% share in Q1 2022, as against 28.5% in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held an 85.5% share in industry sponsored clinical trials in Q1 2022 when compared with an 83.8% average recorded in the last four quarters. Multinational trials accounted for a 14.5% share in Q1 2022, as against the four-quarter average of 16.2%.

Asia-Pacific region held the top position in non-industry sponsored clinical trial activity in Q1 2022 with a 49.8% share, over 50.8% in the last four quarters.

North America held the second position with a 20.5% share in Q1 2022, over 16.4% in the last four quarters, followed by Europe with a 15.2% share in Q1 2022, as against 14.5% in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Single country studies held a 98.8% share for non-industry sponsored clinical trials in Q1 2022, compared to 98.9% in the last four quarters. Multinational trials accounted for a 1.2% share in Q1 2022, as against 1.1% in the last four quarters.

Industry and non-industry sponsored clinical trials by Phase in Q1 2022

Phase II trials outnumbered all other studies with a 39.4% share for industry sponsored trials in Q1 2022, compared to a 35.0% average in the last four quarters.

The share of Phase I trials stood at 31.6% in Q1 2022, as against the four-quarter average of 37.0%. Phase III trials held an 18.3% share in Q1 2022, registering an increase of 2.2% over the last four quarters average, followed by Phase IV trials with a 10.7% share in Q1 2022, as against the four-quarter average of 11.9%.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Phase II trials outnumbered all other trials with a 47.5% share for non-industry sponsored clinical trials in Q1 2022, compared to 41.5% in the last four quarters.

Phase IV trials stood at second place with a 20.4% share in Q1 2022, compared to 23.0% in the last four quarters. Phase I trials held a 17.2% share in Q1 2022, as against 16.0% in the last four quarters, followed by Phase III trials with a 15.0% share in Q1 2022 over a 19.4% average recorded in the last four quarters.

 
  • Embed this chart
    Embed this chart into your website Copy and paste the code below into your website to display the chart.

Methodology:
The clinical trials data used for the analyses were extracted from the Clinical Trials Database of GlobalData’s Pharma Intelligence Center. Clinical Trials are sourced from numerous government, non-government and company clinical trial registries worldwide alongside clinical research publications, scientific conferences, company websites, SEC filings and more. The information is gathered by a combination of automation and secondary research to ensure accuracy and validity. A small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU